F. Guisier

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.

Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).

BACKGROUND Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...

The experiences and satisfaction of patients in outpatient cancer clinics: A scoping review.

PURPOSE The development of outpatient cancer care raises questions regarding the conditions under which such care is delivered. The objective of this study was to conduct an exploratory analysis of the existing literature to better understand the factors contributing to patient satisfaction among adults receiving cance...

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study

Simple Summary In patients with advanced lung cancer harboring targetable gene mutations, sequential immunotherapy-targeted therapy was associated with higher rate of adverse events. A short delay between last immunotherapy administration and targeted therapy administration may increase the risk of serious adverse even...